Peptide Receptor Radionuclide Therapy (PRRT) and Targeted Alpha Therapy (TAT) in Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 29 April 2025 | Viewed by 39
Special Issue Editor
Interests: radiopharmacy; cancer theragnostics imaging and internal radiotherapy; tracer development; glutamate carboxypeptidase II; fibroblast activation protein; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the past two decades, there has been a notable increase in the clinical utilization of diagnostic and therapeutic radiopharmaceuticals in oncology. This has led to the emergence of theranostics as a prominent option for the management of malignant cancers, particularly in cases of metastatic tumors, with very encouraging outcomes being demonstrated.
In view of the encouraging outcomes observed in recent theranostic studies, the introduction of Actinium-225-, Astatine-211-, and Terbium-149-labeled radiopharmaceuticals represents a promising avenue for the development of novel TAT agents in conjunction with Terbium-161 and the established Lutetium-177 PRRT, which, in combination with the predominantly used Ga-68 analog of PRRT agents, serve as a valuable cancer diagnostic tool.
This Special Issue addresses the translational application of novel α- and β-emitters, which present a multitude of opportunities due to their potential to significantly alter the landscape of theranostic studies with PRRT and TAT. The advent of novel technologies is facilitating the expansion of PRRT and TAT applications involving Actinium-225, Astatine-211, Terbium-161, and Terbium-149. This enables the scientific community and pharmaceutical companies to enhance efficiency and provide superior theranostic radiotherapeutics. This development marks an exciting time for the use of theranostics in oncology. However, the rapid growth of this area of nuclear medicine has also created challenges. In particular, the infrastructure used for the manufacturing of radiopharmaceuticals remains under development, and regulatory bodies are still optimizing guidelines for this new class of drug.
Furthermore, the move towards more efficient therapeutic practices represents a significant opportunity, particularly in light of the growing emphasis on quantifying diagnostic and follow-up PET procedures and personalizing dosimetry to achieve therapy management goals.
Prof. Dr. Behrooz H. Yousefi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel radiopharmaceutical synthesis
- translational research
- theranostic studies
- manufacturing of radiopharmaceuticals
- therapy efficacy
- personalized dosimetry
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
